Bring in the narrowest specialist capable of resolving the decision blocker, before work becomes expensive to reverse. Avoid paying a general sourcing adviser to answer a legal question—or paying counsel to reconstruct a disorganised quotation workbook.
| Trigger | Specialist to involve | Deliverable to commission |
|---|---|---|
| Proposed compounding, clinic-stock uncertainty, state mismatch or disputed legal basis | US healthcare/pharmacy counsel | Written assessment of the exact arrangement, unresolved questions and contracting implications |
| Sterile preparation, unexplained inspection findings or technical quality gaps | Pharmacist or pharmaceutical-quality specialist | Product/facility evidence review and targeted corrective-action questions |
| Non-comparable quotes, unclear expenditure control or conflicting contract economics | Independent procurement/finance analyst | Matched workbook, controllable-spend analysis and negotiation agenda |
| Multiple states, pharmacy migration or unreliable status data | Pharmacy operations/integration specialist | Workflow design, acceptance tests and transition runbook |
| Patient-data interfaces or third-party processing | Privacy/security specialist, with counsel as needed | Data-flow assessment, role allocation and required controls |
What should the specialist brief include?
Commission a bounded diagnostic with named products, facilities, states and decisions. Require an evidence register, explicit assumptions, unresolved issues, editable working files and a clear handoff to your internal approvers.
Ask for a fixed scope or fee cap, disclose any supplier-paid remuneration, and keep introductions separate from the evaluation. Do not accept guaranteed savings or automatic legal clearance as deliverables.
How can finance test the economic case?
Compare the fee and implementation burden with evidenced, clinic-attributable opportunities, not total patient medicine expenditure.
Illustrative arithmetic only: a $6,000 diagnostic plus $3,000 of implementation would require $750 a month of net clinic cash savings over twelve months to recover those costs. These are hypothetical inputs—not observed fees, predicted savings or a recommended investment threshold.
Track staff time released separately from cash savings unless it genuinely reduces paid expenditure. Legal and quality reviews should also be assessed as necessary decision controls, not forced into speculative estimates of avoided fines or patient harm.
The practical handoff point: if your team cannot resolve a gating question without guessing, or is about to build or sign around an unresolved assumption, specialist involvement is warranted before proceeding. Whether it saves money depends on the actual scope, fee and outcome.
Explore the table row by row
A working view of the research
Proposed compounding, clinic-stock uncertainty, state mismatch or disputed legal basis
- Specialist to involve
- US healthcare/pharmacy counsel
- Deliverable to commission
- Written assessment of the exact arrangement, unresolved questions and contracting implications
Sources cited on this page
See the section’s source register for the research context.
Section sources →